Tucatinib Shows Promise in Phase I Study of HER2-Positive Breast Cancer

The HER2 TKI tucatinib plus capecitabine or trastuzumab were reasonably well tolerated and showed antitumor activity in a phase I trial of HER2-positive breast cancer.

Source: CancerNetwork - June 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news